Synopsis In recent times, there is an increased prevalence of multidrug-resistant, gram-negative uropathogens. This necessitates consideration of new therapeutic interventions for complicated urinary tract infections (UTIs). Plazomicin is a next-generation aminoglycoside with bactericidal activity against multidrug-resistant Enterobacteriaceae. This drug is active even against Enterobacteriaceae that are resistant to carbapenems which have traditionally been used for the treatment of multidrug-resistant complicated UTIs.
This week’s “ MED FACT ” discusses a phase 3, randomized, multicenter, multinational, double-blind study from the New England Journal of Medicine, ‘ Once-Daily Plazomicin for Complicated Urinary Tract Infections ’, Feb 2019. Authors : Wagenlehner F M E, Cloutier D J, Komirenko A S, et al . Key Takeaways Once-daily plazomicin is an effective treatment strategy for…
